$OCX on NYSE AMERICAN
January 16, 2024
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
December 06, 2023
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
November 09, 2023
Oncocyte Reports Third Quarter 2023 Financial Results
November 03, 2023
Oncocyte to Announce Third Quarter 2023 Financial Results
July 24, 2023
Oncocyte Announces 1-For-20 Reverse Stock Split
June 27, 2023
Oncocyte Begins Manufacturing Transplant Blood Test
May 11, 2023
Oncocyte Reports First Quarter 2023 Financial Results
April 27, 2023
Oncocyte To Announce First Quarter 2023 Financial Results
April 18, 2023
Oncocyte Presents New Data at AACR
April 12, 2023
Oncocyte Announces Reduction in Force
April 07, 2023
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
April 03, 2023
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
March 31, 2023
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
March 29, 2023
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
March 15, 2023
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
February 22, 2023
Oncocyte Completes Razor Genomics Transaction
December 16, 2022
Oncocyte Announces Initiatives to Focus Corporate Strategy
November 30, 2022
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
November 30, 2022
Oncocyte Announces Executive Leadership Changes
November 10, 2022
Oncocyte Reports Third Quarter 2022 Financial Results
October 27, 2022
Oncocyte to Announce Third Quarter 2022 Financial Results
October 06, 2022
DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer
September 07, 2022
Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS
August 31, 2022
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
August 30, 2022
Oncocyte Announces Five-Year VA Contract for DetermaRx
August 24, 2022
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
August 10, 2022
Oncocyte Reports Second Quarter 2022 Financial Results
August 03, 2022
Oncocyte to Participate at Upcoming Investor Conferences
August 01, 2022
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
July 27, 2022
Oncocyte to Announce Second Quarter 2022 Financial Results
July 13, 2022
Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
July 06, 2022
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
June 22, 2022
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
May 26, 2022
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy
May 11, 2022
Oncocyte Reports First Quarter 2022 Financial Results
May 05, 2022
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
April 28, 2022
Oncocyte to Announce First Quarter 2022 Financial Results
April 27, 2022
Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™
April 13, 2022
Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
April 13, 2022
Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
April 13, 2022
Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
April 11, 2022
Oncocyte Presents Confirmatory Data for DetermaIO™ at the American Association for Cancer Research Annual Meeting 2022
March 28, 2022
Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
March 10, 2022
Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 01, 2022
Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10
February 10, 2022
Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 18, 2022
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology
January 04, 2022
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer
December 09, 2021
Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer
- No Recent Filings Found.
